Port Erin Biopharma Investments Ltd (PEBI)

 
Due to recent changes by the London Stock Exchange relating to MiFID II, some AIM stocks are trading off‑book and therefore not showing recent prices, price changes or trades. We are working with the LSE to improve this situation.

PEBI Share PerformanceMore

52 week high9.2500 29/11/16
52 week low4.2500 10/10/17
52 week change -1.7500 (-26.42%)
4 week volume999,440 29/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Net Asset Value(s)

RNS Number: 0094U Port Erin Biopharma Investments Ltd 19 October 2017 19 October 2017 Port Erin Biopharma Investments Limited (the "Company") Net Asset Value calculation to 30 September 2017 Jim Mellon, Chairman, commented: - "The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2017 was 9.20 pence per share, inclu...

NAV & Investment in AgeX Therapeutics Inc.

RNS Number: 6320L Port Erin Biopharma Investments Ltd 20 July 2017 20 July 2017 Port Erin Biopharma Investments Limited (the "Company") Net Asset Value calculation to 30 June 2017 Investment in AgeX Therapeutics Inc. The unaudited Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2017 was 9.35 pence per share, including un-...

Redemption of Interest in Magna Biopharma Fund

RNS Number: 1834D Port Erin Biopharma Investments Ltd 25 April 2017 25 April 2017 Port Erin Biopharma Investments Limited ("Port Erin" or "the Company") Redemption of holding in the Magna Biopharma Income Fund The Company announces that it will redeem for cash its entire holding of 87,125.729 units in the Magna Biopharma Income Fund ("MBIF")...

Net Asset Value(s)

RNS Number: 2482C Port Erin Biopharma Investments Ltd 12 April 2017 12 April 2017 Port Erin Biopharma Investments Limited (the "Company") Net Asset Value calculation to 31 March 2017 Jim Mellon, Chairman, commented: - "The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2017 was 10.56 pence per share, including un-inve...

Port Erin Biopharma swings to H1 pretax profit

Port Erin Biopharma has swung to an H1 pretax profit of 429,311, from a year-ago loss of 184,674. Chairman Jim Mellon sa...

Half-year Report

RNS Number: 8140A Port Erin Biopharma Investments Ltd 29 March 2017 29 March 2017 Port Erin Biopharma Investments Limited ("Port Erin" or the "Company") Interim Results for the six-month period ending 31 December 2016 The Board of Port Erin, the AIM quoted company focused on investing in the biotechnology and biopharmaceutical sectors, is pleased...

Result of AGM

RNS Number: 6642W Port Erin Biopharma Investments Ltd 10 February 2017 10 February 2017 Port Erin Biopharma Investments Limited (the "Company") Results of AGM The Company is pleased to announce that at the AGM held today all the resolutions tabled were duly passed. For further information, please contact: Port Erin Biopharma Investments Limited N...

Net Asset Value(s)

RNS Number: 9529T Port Erin Biopharma Investments Ltd 12 January 2017 Port Erin Biopharma Investments Limited (the "Company") Net Asset Value calculation to 31 December 2016 Jim Mellon, Chairman, commented: - "The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2016 was 11.13 pence per share, including un-invested ...

Fundamental DataMore

EPS-2.3
Dividend yield0 %

Latest discussion posts More

  • Re: Regent Interims / PLE / Fortacin

    http://www.hkexnews.hk/listedco/listconews/sehk/2017/1024/LTN20171024015.pdf
    24-Oct-2017
    IOMINVESTCOM
  • Regent Interims / PLE / Fortacin

    Post the interim reporting period and as announced by the Company on 14 August 2017, the Group has reached an advanced stage of negotiations with Recordati, the Group?s ...
    22-Sep-2017
    IOMINVESTCOM
  • Regent doing welll

    Over the last couple of days Regent Pacific ( PLE ) has bottomed at 0.27 and risen to .35 today up another 10% this morning. http://www.google.com/finance?cid=692487 It ...
    7-Sep-2017
    IOMINVESTCOM

Users' HoldingsMore

Users who hold Port Erin Biopharma Investments Ltd also hold..
QINETIQ50%
Emerging Asia Y Acc25%
FIDELITY CHINA25%
SMURFIT KAP.25%
AFRICAN POTASH25%

Codes & Symbols

ISINIM00B6QH1J21
SymbolsPEBI, LSE:PEBI, PEBI.L, PEBI:LN, LON:PEBI, XLON:PEBI

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account